Variation in Palliative Care Program Performance for Patients With Metastatic Cancer.

Context: While specialist palliative care is associated with improved end-of-life quality metrics for patients with advanced cancer, its effectiveness may differ between hospitals.

Objectives: To examine variation in palliative care program performance on end-of-life care quality metrics.

Methods: Retrospective cohort study of palliative care programs that participated in the National Palliative Care Registry, 2018-2019. Medicare data for patients age ≥65 who died with metastatic cancer were aggregated on a program-level. Variation in program performance on outcomes (use of hospice, hospice enrollment ≥3 days, use of intensive care in the last 30 days of life, and use of chemotherapy in the last 14 days of life) was quantified by risk-standardized outcome rates (RSOR) and adjusted median odds ratios (aMOR).

Results: The cohort comprised 235 palliative care programs who delivered care to 33,015 patients. There was substantial variation in use of hospice (median RSOR 65.6%, interquartile range (IQR) 57.5%-74.3%), hospice enrollment ≥3 days (median RSOR 53.6%, IQR 48.6%-58.2%), and use of intensive care (median RSOR 14.1%, IQR 13.1%-15.3%), but not use of chemotherapy (median RSOR 1.5%, IQR 1.4%-1.5%). Variation was greatest for hospice use (aMOR 1.48 [1.39-1.57]), suggesting that patients at programs with high hospice use would be 48% more likely to use hospice than if they received care at programs with low use.

Conclusion: We found variation in most end-of-life quality metrics for patients with metastatic cancer. Further work is needed to better understand why variations exist and whether such variations reflect a difference in quality of care.